BR112013009043B8 - composto, composição farmacêutica, e, uso de um composto - Google Patents

composto, composição farmacêutica, e, uso de um composto Download PDF

Info

Publication number
BR112013009043B8
BR112013009043B8 BR112013009043A BR112013009043A BR112013009043B8 BR 112013009043 B8 BR112013009043 B8 BR 112013009043B8 BR 112013009043 A BR112013009043 A BR 112013009043A BR 112013009043 A BR112013009043 A BR 112013009043A BR 112013009043 B8 BR112013009043 B8 BR 112013009043B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
blood glucose
diabetes mellitus
type
Prior art date
Application number
BR112013009043A
Other languages
English (en)
Other versions
BR112013009043B1 (pt
BR112013009043A2 (pt
Inventor
Namiki Hidenori
Takahashi Kanako
Matsumoto Koji
Hatta Madoka
Yamanoi Shigeo
Katagiri Takahiro
Yoshitomi Tomomi
Ochiai Yuichi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112013009043A2 publication Critical patent/BR112013009043A2/pt
Publication of BR112013009043B1 publication Critical patent/BR112013009043B1/pt
Publication of BR112013009043B8 publication Critical patent/BR112013009043B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composto, uso de um composto, e, método para tratar uma doença. é fornecido um composto ou um sal farmaceuticamente acietável do mesmo representado pela fórmula geral (i) que tem um efeito que diminui a glicose sanguína excelente e efeito protetor sobre as células <225> ou pâncreas excelente e também é fornecida uma composição farmacêutica tendo um efeito terapêutico ou profilático excelente contra a diabete melito tipo 1, diabete melito tipo 2 e outras de tais doenças na quais a glicose sanguínea aumenta em resposta ás anomalias do metabolismo de açúcar.
BR112013009043A 2010-10-14 2011-10-13 composto, composição farmacêutica, e, uso de um composto BR112013009043B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2010-231471 2010-10-14
JP2010231471 2010-10-14
JP2011-022325 2011-02-04
JP2011022325 2011-02-04
PCT/JP2011/073489 WO2012050151A1 (ja) 2010-10-14 2011-10-13 アシルベンゼン誘導体

Publications (3)

Publication Number Publication Date
BR112013009043A2 BR112013009043A2 (pt) 2016-07-26
BR112013009043B1 BR112013009043B1 (pt) 2019-06-18
BR112013009043B8 true BR112013009043B8 (pt) 2019-09-17

Family

ID=45938375

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009043A BR112013009043B8 (pt) 2010-10-14 2011-10-13 composto, composição farmacêutica, e, uso de um composto

Country Status (27)

Country Link
US (1) US8722711B2 (pt)
EP (1) EP2628733B1 (pt)
JP (2) JP5069813B2 (pt)
KR (1) KR101829086B1 (pt)
CN (1) CN103249726B (pt)
AU (1) AU2011314712B2 (pt)
BR (1) BR112013009043B8 (pt)
CA (1) CA2814628C (pt)
CO (1) CO6771403A2 (pt)
CY (1) CY1116303T1 (pt)
DK (1) DK2628733T3 (pt)
ES (1) ES2532706T3 (pt)
HK (1) HK1185082A1 (pt)
HR (1) HRP20150225T1 (pt)
IL (1) IL225724A (pt)
MX (1) MX2013004176A (pt)
MY (1) MY160300A (pt)
NZ (1) NZ610145A (pt)
PL (1) PL2628733T3 (pt)
PT (1) PT2628733E (pt)
RS (1) RS53965B1 (pt)
RU (1) RU2585765C2 (pt)
SG (1) SG189320A1 (pt)
SI (1) SI2628733T1 (pt)
SM (1) SMT201500067B (pt)
TW (1) TWI487699B (pt)
WO (1) WO2012050151A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014102743A (ru) * 2011-07-29 2015-09-10 Дайити Санкио Компани, Лимитед Амидное производное, замещенное n-гетероциклическим кольцом
CA2861847A1 (en) * 2012-01-18 2013-07-25 Daiichi Sankyo Company, Limited Substituted phenylazole derivative
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
WO2017104782A1 (ja) * 2015-12-17 2017-06-22 第一三共株式会社 オキサジアゾール化合物の製造方法
TW201731506A (zh) * 2016-01-19 2017-09-16 第一三共股份有限公司 糖尿病治療劑之倂用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4401108A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 1,2,4-Oxadiazol-Derivate
PL339673A1 (en) * 1997-10-06 2001-01-02 Lilly Co Eli Novel compounds suitable for use as neuroprotective agents
JP2004506722A (ja) * 2000-08-23 2004-03-04 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体の調節方法
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
NZ547965A (en) 2003-12-24 2009-12-24 Prosidion Ltd 1,2,4-Oxadiazole derivatives as GPCR receptor agonists
GB0513257D0 (en) * 2005-06-30 2005-08-03 Prosidion Ltd Compounds
JP5114395B2 (ja) * 2005-06-30 2013-01-09 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
BRPI0613505A2 (pt) 2005-06-30 2011-01-11 Prosidion Ltd agonistas de gpcr
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
MX2008012814A (es) 2006-04-06 2008-10-17 Prosidion Ltd Agonistas del receptor acoplado a la proteina g heterociclicos.
EP2241558A1 (en) 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
ES2439801T3 (es) 2009-08-05 2014-01-24 Daiichi Sankyo Company, Limited Derivado de sulfona
KR20120051670A (ko) * 2009-08-05 2012-05-22 다이이찌 산쿄 가부시키가이샤 아미드 유도체
GB201006166D0 (en) * 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
SI2628733T1 (sl) 2015-10-30
JP5869985B2 (ja) 2016-02-24
CY1116303T1 (el) 2017-02-08
JPWO2012050151A1 (ja) 2014-02-24
CN103249726A (zh) 2013-08-14
RU2013121816A (ru) 2014-11-20
IL225724A (en) 2015-10-29
DK2628733T3 (en) 2015-03-30
SG189320A1 (en) 2013-05-31
KR101829086B1 (ko) 2018-02-13
PT2628733E (pt) 2015-03-24
EP2628733A4 (en) 2014-02-26
CO6771403A2 (es) 2013-10-15
AU2011314712B2 (en) 2016-05-26
SMT201500067B (it) 2015-05-05
HRP20150225T1 (hr) 2015-06-19
PL2628733T3 (pl) 2015-05-29
JP5069813B2 (ja) 2012-11-07
CN103249726B (zh) 2015-01-07
HK1185082A1 (en) 2014-02-07
US20130217733A1 (en) 2013-08-22
JP2012224640A (ja) 2012-11-15
US8722711B2 (en) 2014-05-13
IL225724A0 (en) 2013-06-27
TW201305121A (zh) 2013-02-01
KR20130099094A (ko) 2013-09-05
ES2532706T3 (es) 2015-03-31
TWI487699B (zh) 2015-06-11
RS53965B1 (en) 2015-08-31
AU2011314712A1 (en) 2013-05-02
BR112013009043B1 (pt) 2019-06-18
MY160300A (en) 2017-02-28
EP2628733A1 (en) 2013-08-21
EP2628733B1 (en) 2014-12-24
MX2013004176A (es) 2013-10-25
NZ610145A (en) 2015-02-27
CA2814628A1 (en) 2012-04-19
RU2585765C2 (ru) 2016-06-10
BR112013009043A2 (pt) 2016-07-26
CA2814628C (en) 2015-06-16
WO2012050151A1 (ja) 2012-04-19

Similar Documents

Publication Publication Date Title
AU2016202421B2 (en) Method of treating neurological conditions with cardiac glycosides
AR083679A1 (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos
BR112014007310A2 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
NZ623454A (en) Pharmaceutical composition for the treatment of heart diseases
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
UA95105C2 (ru) Применение производного лактамида для снижения токсичности в препарате, который может соприкасаться с кожей или глазами человека или животного, производные лактамида и способы их получения
CO6410287A2 (es) Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
WO2009152189A8 (en) Low dose topiramate/phentermine compostion and methods of use thereof
BR112012026211A2 (pt) combinações de composto ativo
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
WO2015157559A3 (en) 10&#39;,11&#39;-modified saxitoxins useful for the treatment of pain
WO2011011882A8 (en) Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
BR112013009043B8 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112012006010A2 (pt) composto de glicina
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MX2009011554A (es) Preparacion solida estable conteniendo un derivado de 4,5-epoximorfinano.
BR112012006172A2 (pt) derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
NZ594184A (en) Skin treatment

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2011, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2011, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2011, OBSERVADAS AS CONDICOES LEGAIS. (CO) REF. RPI 2528 DE 18/06/2019 QUANTO AO ITEM (54) TITULO E A MINTAGEM DO RELATORIO DESCRITIVO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 10A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.